Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis

Children with TB meningitis do poorly, and this paper examines the pharmacokinetics of a commonly used drug combination to understand if drug factors contribute. Objective To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Design Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis. Setting Hasan Sadikin Hospital, Bandung, Indonesia. Patients Individuals aged 0-18 years clinically diagnosed with TBM and receiving first-line anti-tuberculosis drug dosages according to revised WHO-recommended treatment guidelines. Interventions Plasma and cerebrospinal fluid (CSF) concentrations of isoniazid, rifampicin and pyrazinamide were assessed on days 2 and 10 of treatment. Main outcome measures Plasma exposures during the daily dosing interval (AUC(0-24)), peak plasma concentrations (C (max)) and CSF concentrations. Results Among 20 eligible patients, geometric mean AUC(0-24) of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour center dot mg/L on day 2; and 14.5, 71.8 and 328.4 hour center dot mg/L on day 10, respectively. Large interindividual variabilities were observed in AUC(0-24) and C (max) of all drugs. All patients had suboptimal rifampicin AUC(0-24) for TBM treatment indication and very low rifampicin CSF concentrations. Four patients developed grade 2-3 drug-induced liver injury (DILI) within the first 4 weeks of treatment, in whom anti-tuberculosis drugs were temporarily stopped, and no DILI recurred after reintroduction of rifampicin and isoniazid. AUC(0-24) of isoniazid, rifampicin and pyrazinamide along with C (max) of isoniazid and pyrazinamide on day 10 were higher in patients who developed DILI than those without DILI (p<0.05). Conclusion Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies.

Automated summary

This study examined the pharmacokinetics and safety of isoniazid, rifampicin, and pyrazinamide in children and adolescents with tuberculous meningitis. It found that higher doses of rifampicin are needed for the treatment of TBM in this population, and that there was an association between higher plasma concentrations of isoniazid, rifampicin, and pyrazinamide and the development of drug-induced liver injury. Further confirmatory studies are needed to validate these findings.